Glaukos (GKOS) President & COO earns 7,316 stock options after goals met

Rhea-AI Filing Summary

Glaukos Corp reported that its President and COO acquired 7,316 stock options on 12/11/2025 under a previously granted award tied to pre-determined operational targets. These options have an exercise price of $55.18 and were earned after the Compensation, Nominating & Governance Committee determined that certain operational targets over a multi-year performance period had been achieved.

The options represent a portion of an award originally granted on March 24, 2022, and will vest in two equal installments, with 50% becoming exercisable in March 2026 and the remaining 50% in December 2026. Following this transaction, the executive beneficially owned 65,013 derivative securities, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gilliam Joseph E

(Last) (First) (Middle)

C/O GLAUKOS CORPORATION

ONE GLAUKOS WAY

(Street)

ALISO VIEJO CA 92656

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GLAUKOS Corp [ GKOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT & COO

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$55.18	12/11/2025		A		7,316(1)		(2)	03/24/2032	Common Stock	7,316	$0	65,013	D

Explanation of Responses:

1. Represents a portion of an option to purchase shares of common stock previously granted by the Issuer on March 24, 2022, the vesting of which was subject to the Issuer's achievement of certain pre-determined operational targets over a multi-year performance period. The Compensation, Nominating & Governance Committee of the Issuer's Board of Directors determined that certain of the operational targets had been achieved. The number of shares of common stock subject to the stock option as reported herein consists of the portion of the award that was earned based upon the achievement of the operational targets.

2. 50% of the portion of the option reported herein will vest and become exercisable in March 2026. 50% of the portion of the option reported herein will vest and become exercisable in December 2026.

	Diana Scherer, Attorney-in-Fact	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Glaukos (GKOS) report in this Form 4?

The filing reports that the President and COO acquired 7,316 stock options on 12/11/2025 as part of a previously granted equity award tied to operational targets.

How many stock options did the Glaukos (GKOS) President & COO earn and at what exercise price?

The executive earned 7,316 stock options, each with an exercise price of $55.18 for shares of Glaukos common stock.

When was the underlying Glaukos (GKOS) option award originally granted?

The reported portion relates to an option to purchase shares of common stock that was originally granted on March 24, 2022.

Why did the Glaukos (GKOS) options become earned in this transaction?

The options became earned after the Compensation, Nominating & Governance Committee determined that certain pre-determined operational targets over a multi-year performance period had been achieved.

What is the vesting schedule for the Glaukos (GKOS) options reported?

According to the filing, 50% of the reported option portion will vest and become exercisable in March 2026, and the remaining 50% will vest and become exercisable in December 2026.

How many derivative securities does the Glaukos (GKOS) executive hold after this transaction?

Following the transaction, the executive beneficially owned 65,013 derivative securities, all reported as held directly.